Report Highlights

Pheochromocytoma in the United States: Market Overview

The U.S. pheochromocytoma market is a rare-disease niche within the broader neuroendocrine tumor segment, valued at USD 310 million in 2024 by this analysis. Annual incidence sits near one case per 100,000 people, but diagnosed prevalence is rising as biochemical screening of incidental adrenal masses and germline surveillance identify more patients. Unlike global volume markets, the U.S. is value-heavy, driven by specialty imaging, radioligand therapy and tertiary surgery.

Market structure departs from global norms in its concentration of care. Diagnosis and treatment cluster in a limited number of academic endocrine and surgical centers, including Mayo Clinic, Johns Hopkins and the NIH Clinical Center, which act as referral hubs for genetic and imaging work. Pricing is orphan-driven: metyrosine and phenoxybenzamine carry premium list prices with thin generic competition, so reimbursement runs through Medicare Part D and commercial formularies rather than tender-based volume contracts.

Growth Drivers in U.S. Pheochromocytoma Care

Three country-specific demand drivers are accelerating volume. First, National Comprehensive Cancer Network guidance recommends germline genetic testing for all pheochromocytoma and paraganglioma patients, expanding diagnosed cases in RET, VHL, NF1 and SDHB carriers. Second, Medicare covers gallium-68 DOTATATE PET imaging, which Netspot and Detectnet have made a leading tool for localizing tumors. Third, adults over 65 undergo more frequent adrenal imaging, raising incidental adrenal findings that clinicians across the country now route into biochemical workups.

Surgical volume reinforces pharmacologic demand. Every candidate for adrenalectomy needs preoperative alpha-blockade with phenoxybenzamine or doxazosin, and metyrosine adds control when catecholamine surges are severe, so each resection generates weeks of prescription fills. Radioligand interest also persists after Lantheus discontinued Azedra in 2024, because clinicians still seek iodine-131 MIBG and Lutathera-class options for metastatic patients who progress on standard care. Medical oncologists at these centers increasingly coordinate both approaches within single tumor boards.

Market Restraints and Entry Barriers in the U.S.

Entry faces three structural barriers. Radiopharmaceuticals require NRC or Agreement State licensing under 10 CFR Part 35, and iodine-131 therapy demands shielded inpatient beds, limiting facilities able to administer treatment. Genetic and biochemical testing must meet CLIA certification under 42 CFR Part 493, while small patient populations make enrollment in pivotal trials slow and expensive for sponsors. Sponsors therefore struggle to build evidence packages large enough for payer reviews.

Incumbent advantages are entrenched. Academic referral centers hold established relationships with Novartis, Curium US and GE HealthCare imaging programs, while surgical volume concentrates in a few robotic adrenalectomy programs using Intuitive Surgical platforms. Pricing controls compound this: Medicare reimbursement for PET scans is fixed under the physician fee schedule, and 340B discount rules complicate pricing for entrants selling into hospital outpatient departments. Newcomers must therefore win formulary placement through clinical data rather than price.

Market Opportunities in U.S. Pheochromocytoma Care

Near-term entry points center on metastatic and inoperable disease. Analyst estimates place U.S. new pheochromocytoma and paraganglioma diagnoses at roughly 1,500 to 2,000 annually, with about 10 to 15 percent metastatic at presentation, creating an addressable base of roughly 150 to 300 patients per year for radioligand therapy. Entrants with dosimetry partnerships or iodine-131 supply agreements can serve these patients through academic oncology centers within three years.

Diagnostic services offer a second opportunity. Plasma free metanephrine assays and germline panels are increasingly bundled into hereditary cancer programs, and Myriad Genetics and similar laboratories are expanding reflex testing for every newly diagnosed adrenal mass. Telehealth-enabled endocrine follow-up for SDHB carriers, who face higher malignancy risk, also offers an underserved surveillance niche in rural states where specialists are scarce.

Market at a Glance

Leading Market Participants

• Novartis
• Lantheus
• Curium US
• GE HealthCare
• Bracco Imaging
• Cardinal Health
• Jubilant Radiopharma
• Intuitive Surgical
• Myriad Genetics
• Concordia Pharmaceuticals

Regulatory and Policy Environment in the U.S.

The FDA regulates pheochromocytoma therapeutics through the Center for Drug Evaluation and Research and the Orphan Drug Act of 1983, which grants seven years of market exclusivity and a 25 percent orphan drug tax credit under Internal Revenue Code Section 45C for qualified clinical testing. Standard NDA review targets roughly ten months after the 60-day filing period, while radiopharmaceutical manufacturing falls under FDA current good manufacturing practice rules and NRC licensing.

Diagnostic and therapeutic delivery depend on CMS coverage decisions, CLIA-certified laboratories under 42 CFR Part 493, and Agreement State programs that license nuclear medicine facilities. Compliance timelines matter: a new radioligand therapy entrant should expect 12 to 18 months for NRC or state license amendments, plus Medicare coverage processes that typically span several months.

Long-Term Outlook for U.S. Pheochromocytoma

By 2032, the U.S. pheochromocytoma market should reach roughly USD 450 million, growing at a 4.8% CAGR from the 2025 base year. Growth will concentrate in genetic-driven diagnostics and radioligand therapy, where a new iodine-131 MIBG or peptide radioligand entrant could redefine the treatment ladder. Surgical volumes will stay stable while preoperative pharmacology expands with better catecholamine monitoring.

The market will consolidate around a few imaging, radiopharmaceutical and drug suppliers, with Novartis, Curium US and GE HealthCare holding the strongest referral-center positions. Genetic testing volume is the sharpest growth lever, but surveillance imaging reimbursement will determine whether that demand converts into revenue for entrants.